Loading...
Please wait, while we are loading the content...
Similar Documents
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
| Content Provider | Scilit |
|---|---|
| Author | Halpern, Rachel Agarwal, Sonalee Dembek, Carole Borton, Leigh |
| Copyright Year | 2011 |
| Description | Journal: Patient preference and adherence |
| Abstract | Purpose: To compare adherence and persistence among patients with multiple sclerosis (MS) initiated on disease-modifying therapy (DMTs), including intramuscular (IM) interferon beta-1a (IFNβ-1a), subcutaneous (SC) IFNβ-1a, IFNβ-1b, or glatiramer acetate (GA). Methods: MS patients initiated on IM-IFNβ-1a, SC-IFNβ-1a, IFNβ-1b, or GA between January 1, 2000 and January 2, 2008 were identified from a retrospective claims database study associated with a large US health plan. The date of DMT initiation was the index date; patients were observed for 6 months before and 12–36 months after the index date. Adherence to the index DMT was measured with a medication possession ratio (MPR), the proportion of days patients possessed their index DMTs; MPR ≥0.80 was considered adherent. Persistence was time in days from index date until the earlier of a minimum 60-day gap in DMT therapy or the last DMT claim during follow-up. Adherence and persistence were modeled with logistic and Cox proportional hazard regressions, respectively. Results: The study population comprised 6,680 patients in the DMT cohorts: IM-IFNβ-1a (N = 2,305, 34.5%); IFNβ-1b (N = 894, 13.4%); GA (N = 2,270, 34.0%); and SC-IFNβ-1a (N = 1,211, 18.1%). The IM-IFNβ-1a cohort had significantly higher regression-adjusted odds of adherence relative to the other cohorts: 52.4% higher odds versus the IFNβ-1b cohort (OR = 0.656, CI = 0.561–0.768); 33.5% higher odds versus the GA cohort (OR = 0.749, CI = 0.665–0.844); and 20.6% higher odds versus the SC-IFNβ-1a cohort (OR = 0.829, CI = 0.719–0.957). There were no consistent differences in persistence between the cohorts. Conclusion: IM-IFNβ-1a patients had significantly higher odds of adherence compared with other DMT cohorts, possibly attributable to IM-IFNβ-1a’s less frequent dosing schedule. The benefits of adherence may include better quality of life, lower risk of relapse, and fewer hospitalizations and emergency visits, making adherence a critical component of MS management. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058604/pdf https://www.dovepress.com/getfile.php?fileID=8604 |
| Ending Page | 84 |
| Page Count | 12 |
| Starting Page | 73 |
| ISSN | 1177889X |
| DOI | 10.2147/ppa.s15702 |
| Journal | Patient preference and adherence |
| Volume Number | 5 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2011-01-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Patient preference and adherence Public Health and Health Services Multiple Sclerosis Immunomodulatory Therapy Patient Compliance |
| Content Type | Text |
| Subject | Social Sciences Pharmacology, Toxicology and Pharmaceutics Health Policy |
